| pubmed-article:6499925 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:6499925 | lifeskim:mentions | umls-concept:C0042396 | lld:lifeskim |
| pubmed-article:6499925 | lifeskim:mentions | umls-concept:C0042401 | lld:lifeskim |
| pubmed-article:6499925 | lifeskim:mentions | umls-concept:C0022616 | lld:lifeskim |
| pubmed-article:6499925 | lifeskim:mentions | umls-concept:C0680242 | lld:lifeskim |
| pubmed-article:6499925 | pubmed:issue | 3-4 | lld:pubmed |
| pubmed-article:6499925 | pubmed:dateCreated | 1984-12-28 | lld:pubmed |
| pubmed-article:6499925 | pubmed:abstractText | The effect of ketanserin on the action of 5-hydroxytryptamine (5-HT) and noradrenaline has been studied using the rat isolated perfused mesentery preparation. Both 5-HT and noradrenaline produced constriction in the mesenteric vessels. The responses to 5-HT and noradrenaline were greater in tissues from hypertensive animals. Responses to 5-HT were abolished by 1 nM ketanserin. Ketanserin was found to be a competitive antagonist of the noradrenaline-induced constrictions (pA2 = 7.5). In partially constricted tissues, 5-HT induced vasoconstriction and vasodilation. In the presence of ketanserin the vasoconstriction was reduced and the 5-HT-induced vasodilation was potentiated. The amount of potentiation of the 5-HT-induced vasodilation by ketanserin was similar in tissues from normotensive and hypertensive rats. It is suggested that the 5-HT-induced vasoconstriction is mediated by activation of 5-HT2 receptors. In the presence of ketanserin, the 5-HT2 receptor mediated vasoconstriction is antagonized, unmasking a 5-HT-induced vasodilation. | lld:pubmed |
| pubmed-article:6499925 | pubmed:language | eng | lld:pubmed |
| pubmed-article:6499925 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6499925 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:6499925 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6499925 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6499925 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6499925 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6499925 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6499925 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6499925 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6499925 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6499925 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:6499925 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:6499925 | pubmed:issn | 0014-2999 | lld:pubmed |
| pubmed-article:6499925 | pubmed:author | pubmed-author:TaylorD ADA | lld:pubmed |
| pubmed-article:6499925 | pubmed:author | pubmed-author:McLennanP LPL | lld:pubmed |
| pubmed-article:6499925 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:6499925 | pubmed:day | 17 | lld:pubmed |
| pubmed-article:6499925 | pubmed:volume | 104 | lld:pubmed |
| pubmed-article:6499925 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:6499925 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:6499925 | pubmed:pagination | 313-8 | lld:pubmed |
| pubmed-article:6499925 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:6499925 | pubmed:meshHeading | pubmed-meshheading:6499925-... | lld:pubmed |
| pubmed-article:6499925 | pubmed:meshHeading | pubmed-meshheading:6499925-... | lld:pubmed |
| pubmed-article:6499925 | pubmed:meshHeading | pubmed-meshheading:6499925-... | lld:pubmed |
| pubmed-article:6499925 | pubmed:meshHeading | pubmed-meshheading:6499925-... | lld:pubmed |
| pubmed-article:6499925 | pubmed:meshHeading | pubmed-meshheading:6499925-... | lld:pubmed |
| pubmed-article:6499925 | pubmed:meshHeading | pubmed-meshheading:6499925-... | lld:pubmed |
| pubmed-article:6499925 | pubmed:meshHeading | pubmed-meshheading:6499925-... | lld:pubmed |
| pubmed-article:6499925 | pubmed:meshHeading | pubmed-meshheading:6499925-... | lld:pubmed |
| pubmed-article:6499925 | pubmed:meshHeading | pubmed-meshheading:6499925-... | lld:pubmed |
| pubmed-article:6499925 | pubmed:meshHeading | pubmed-meshheading:6499925-... | lld:pubmed |
| pubmed-article:6499925 | pubmed:meshHeading | pubmed-meshheading:6499925-... | lld:pubmed |
| pubmed-article:6499925 | pubmed:meshHeading | pubmed-meshheading:6499925-... | lld:pubmed |
| pubmed-article:6499925 | pubmed:meshHeading | pubmed-meshheading:6499925-... | lld:pubmed |
| pubmed-article:6499925 | pubmed:meshHeading | pubmed-meshheading:6499925-... | lld:pubmed |
| pubmed-article:6499925 | pubmed:year | 1984 | lld:pubmed |
| pubmed-article:6499925 | pubmed:articleTitle | Antagonism by ketanserin of 5-HT-induced vasoconstriction unmasks a 5-HT-induced vasodilation. | lld:pubmed |
| pubmed-article:6499925 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:6499925 | pubmed:publicationType | In Vitro | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6499925 | lld:pubmed |
